These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 22614886)

  • 1. Early antiretroviral therapy improves neurodevelopmental outcomes in infants.
    Laughton B; Cornell M; Grove D; Kidd M; Springer PE; Dobbels E; van Rensburg AJ; Violari A; Babiker AG; Madhi SA; Jean-Philippe P; Gibb DM; Cotton MF
    AIDS; 2012 Aug; 26(13):1685-90. PubMed ID: 22614886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Five year neurodevelopment outcomes of perinatally HIV-infected children on early limited or deferred continuous antiretroviral therapy.
    Laughton B; Cornell M; Kidd M; Springer PE; Dobbels EFM; Rensburg AJV; Otwombe K; Babiker A; Gibb DM; Violari A; Kruger M; Cotton MF
    J Int AIDS Soc; 2018 May; 21(5):e25106. PubMed ID: 29722482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early time-limited antiretroviral therapy versus deferred therapy in South African infants infected with HIV: results from the children with HIV early antiretroviral (CHER) randomised trial.
    Cotton MF; Violari A; Otwombe K; Panchia R; Dobbels E; Rabie H; Josipovic D; Liberty A; Lazarus E; Innes S; van Rensburg AJ; Pelser W; Truter H; Madhi SA; Handelsman E; Jean-Philippe P; McIntyre JA; Gibb DM; Babiker AG;
    Lancet; 2013 Nov; 382(9904):1555-63. PubMed ID: 24209829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reactivity of routine HIV antibody tests in children who initiated antiretroviral therapy in early infancy as part of the Children with HIV Early Antiretroviral Therapy (CHER) trial: a retrospective analysis.
    Payne H; Mkhize N; Otwombe K; Lewis J; Panchia R; Callard R; Morris L; Babiker A; Violari A; Cotton MF; Klein NJ; Gibb DM
    Lancet Infect Dis; 2015 Jul; 15(7):803-9. PubMed ID: 26043884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early virological suppression with three-class antiretroviral therapy in HIV-infected African infants.
    Prendergast A; Mphatswe W; Tudor-Williams G; Rakgotho M; Pillay V; Thobakgale C; McCarthy N; Morris L; Walker BD; Goulder P
    AIDS; 2008 Jul; 22(11):1333-43. PubMed ID: 18580613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurodevelopmental delay among HIV-infected preschool children receiving antiretroviral therapy and healthy preschool children in Soweto, South Africa.
    Lowick S; Sawry S; Meyers T
    Psychol Health Med; 2012; 17(5):599-610. PubMed ID: 22313239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pulmonary effects of immediate versus deferred antiretroviral therapy in HIV-positive individuals: a nested substudy within the multicentre, international, randomised, controlled Strategic Timing of Antiretroviral Treatment (START) trial.
    Kunisaki KM; Niewoehner DE; Collins G; Aagaard B; Atako NB; Bakowska E; Clarke A; Corbelli GM; Ekong E; Emery S; Finley EB; Florence E; Infante RM; Kityo CM; Madero JS; Nixon DE; Tedaldi E; Vestbo J; Wood R; Connett JE;
    Lancet Respir Med; 2016 Dec; 4(12):980-989. PubMed ID: 27773665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early antiretroviral treatment reduces risk of bacille Calmette-Guérin immune reconstitution adenitis.
    Rabie H; Violari A; Duong T; Madhi SA; Josipovic D; Innes S; Dobbels E; Lazarus E; Panchia R; Babiker AG; Gibb DM; Cotton MF;
    Int J Tuberc Lung Dis; 2011 Sep; 15(9):1194-200, i. PubMed ID: 21943845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cognitive function and neurodevelopmental outcomes in HIV-infected Children older than 1 year of age randomized to early versus deferred antiretroviral therapy: the PREDICT neurodevelopmental study.
    Puthanakit T; Ananworanich J; Vonthanak S; Kosalaraksa P; Hansudewechakul R; van der Lugt J; Kerr SJ; Kanjanavanit S; Ngampiyaskul C; Wongsawat J; Luesomboon W; Vibol U; Pruksakaew K; Suwarnlerk T; Apornpong T; Ratanadilok K; Paul R; Mofenson LM; Fox L; Valcour V; Brouwers P; Ruxrungtham K;
    Pediatr Infect Dis J; 2013 May; 32(5):501-8. PubMed ID: 23263176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early antiretroviral therapy and mortality among HIV-infected infants.
    Violari A; Cotton MF; Gibb DM; Babiker AG; Steyn J; Madhi SA; Jean-Philippe P; McIntyre JA;
    N Engl J Med; 2008 Nov; 359(21):2233-44. PubMed ID: 19020325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV-associated neurodevelopmental delay: prevalence, predictors and persistence in relation to antiretroviral therapy initiation and viral suppression.
    Strehlau R; Kuhn L; Abrams EJ; Coovadia A
    Child Care Health Dev; 2016 Nov; 42(6):881-889. PubMed ID: 27546069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of developmental milestone attainment in early treated HIV-infected infants versus HIV-unexposed infants: a prospective cohort study.
    Benki-Nugent S; Wamalwa D; Langat A; Tapia K; Adhiambo J; Chebet D; Okinyi HM; John-Stewart G
    BMC Pediatr; 2017 Jan; 17(1):24. PubMed ID: 28095807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimisation of antiretroviral therapy in HIV-infected children under 3 years of age.
    Penazzato M; Prendergast AJ; Muhe LM; Tindyebwa D; Abrams E
    Cochrane Database Syst Rev; 2014 May; 2014(5):CD004772. PubMed ID: 24852077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Virologic, immunologic, and clinical benefits from early combined antiretroviral therapy in infants with perinatal HIV-1 infection.
    Chiappini E; Galli L; Tovo PA; Gabiano C; Gattinara GC; Guarino A; Badolato R; Giaquinto C; Lisi C; de Martino M;
    AIDS; 2006 Jan; 20(2):207-15. PubMed ID: 16511413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of antiretroviral therapy in HIV-infected children under 2 years of age.
    Penazzato M; Prendergast A; Tierney J; Cotton M; Gibb D
    Cochrane Database Syst Rev; 2012 Jul; (7):CD004772. PubMed ID: 22786492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Infectious morbidity of breastfed, HIV-exposed uninfected infants under conditions of universal antiretroviral therapy in South Africa: a prospective cohort study.
    le Roux SM; Abrams EJ; Donald KA; Brittain K; Phillips TK; Zerbe A; le Roux DM; Kroon M; Myer L
    Lancet Child Adolesc Health; 2020 Mar; 4(3):220-231. PubMed ID: 31932246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neurodevelopment at 11 months after starting antiretroviral therapy within 3 weeks of life.
    Laughton B; Naidoo S; Dobbels EFMT; Boivin MJ; van Rensburg AJ; Glashoff RH; van Zyl GU; Kruger M; Cotton MF
    South Afr J HIV Med; 2019; 20(1):1008. PubMed ID: 31745434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High frequency of rapid immunological progression in African infants infected in the era of perinatal HIV prophylaxis.
    Mphatswe W; Blanckenberg N; Tudor-Williams G; Prendergast A; Thobakgale C; Mkhwanazi N; McCarthy N; Walker BD; Kiepiela P; Goulder P
    AIDS; 2007 Jun; 21(10):1253-61. PubMed ID: 17545701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimal time for initiating antiretroviral therapy (ART) in HIV-infected, treatment-naive children aged 2 to 5 years old.
    Siegfried N; Davies MA; Penazzato M; Muhe LM; Egger M
    Cochrane Database Syst Rev; 2013 Oct; 10(10):CD010309. PubMed ID: 24114324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Massage therapy improves the development of HIV-exposed infants living in a low socio-economic, peri-urban community of South Africa.
    Perez EM; Carrara H; Bourne L; Berg A; Swanevelder S; Hendricks MK
    Infant Behav Dev; 2015 Feb; 38():135-46. PubMed ID: 25645599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.